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background: Calculated LDL-C by Friedewald formula has been the basis for clinical and regulatory decision making for 40 years. The validity has 
recently been questioned as clinical guidelines and new therapeutic agents reduce LDL-C levels to below levels originally validated by Friedewald. 
We compare LDL-C by Friedewald and the ‘gold standard’, preparative ultracentrifugation (PUC) in 60,451 samples with 19,427 ≤70 mg/dL.
methods: Serum samples from patients in clinical trials over the last 6 years analyzed by Friedewald and PUC were compared, in a central 
laboratory CDC-NHLBI Part 3Standardized for lipid measurements, and clinically important cutpoints of 100, 70, 50 and 25 mg/dL and within each 
cutpoint by triglyceride (TG) levels assessed.
results: See Table. For LDL-C >100 mg/dL there was minimal difference between methods. Differences became apparent between 100 and 
70 mg/dL and calculated LDL-C at 51-70, 26-50 and ≤25 mg/dL averaged 5.7, 8.8 and 28.2% lower than by PUC, respectively. Friedewald 
underestimated PUC LDL-C for each 100 mg/dL TG increase above 100 mg/dL by 33, 57 and 66% when LDL-C was <25 mg/dL.
conclusion: As Friedewald accurately measures LDL-C >100 mg/dL, the usual entry for clinical trials, but significantly underestimates LDL-C <70 
mg/dL it overestimates the apparent reduction with treatment. This overestimation increases at even lower LDL-C and is compounded by even 
moderate TG elevations. This has major consequences for new LDL-C lowering drug development and outcome trials.
 
